High-dose methotrexate (HDMTX) is a component of most treatment protocols for childhood acute lymphoblastic leukemia (ALL), yet recent studies of receptor-mediated transport and saturable polyglutamylation have questioned its rationale. To investigate this in vivo, methotrexate and its active polyglutamated metabolites (MTX-PG) were measured in bone marrow blasts obtained from 101 children randomized to single-agent therapy with either HDMTX (1 g/m2 per 24 h i.v., n = 47) or low-dose MTX (LDMTX, 30 mg/m2 by mouth every 6 h x 6, n = 54), before remission induction therapy. Blast concentrations of total MTX-PGs (median 460 vs 1380 pmol/109 cells) and of long-chain MTXgu4-6 were both significantly higher after HDMTX (P < 0.001). With either treatment, MTX-PGs were significantly higher in B-lineage blasts than in T-lineage blasts (LDMTX P = 0.001, HDMTX P = 0.03). In a multiple regression analysis of B-lineage ALL, blast MTX-PG was significantly related to MTX dose (or plasma MTX concentration), lymphoblast ploidy (hyperdiploid > nonhyperdiploid), and percentage S-phase. This is the first evidence that HDMTX achieves higher MTX-PG concentrations in ALL blasts in vivo, establishing a rationale for HDMTX in the treatment of childhood ALL, especially T-lineage or nonhyperdiploid B-lineage ALL, disease characteristics associated with a poor prognosis on conventional therapy. (J. Clin. Invest.
Introduction
Despite several decades of clinical evaluation, the optimal dosage of methotrexate (MTX)1 for the treatment of childhood acute lymphoblastic leukemia (ALL) remains controversial. While most investigators agree that weekly administration of low doses (e.g., 40 mg/m2) is appropriate for therapy during remission, there is no consensus regarding the rationale for highdose MTX (e.g., 1000 mg/m2 i.v. over 24 h) as a component of ALL treatment. Although several treatment regimens with improved outcome included high-dose MTX (HDMTX) (1) (2) (3) , in vitro studies have suggested that low-dose MTX (LDMTX) can achieve comparable intracellular concentrations at lower cost and with less inconvenience (4) (5) (6) . Investigators favoring LDMTX argue that receptor-mediated MTX transport via potocytosis (7) is maximal at extracellular MTX concentrations of 0.05-0.1 4M in receptor-positive cells, and that chronic exposure to low concentrations will achieve intracellular concentrations comparable to HDMTX treatment (6) . Those advocating HDMTX contend that higher extracellular MTX concentrations will lead to increased entry of MTX into cells by alternative mechanisms (e.g., passive diffusion), including resistant blasts with reduced active membrane transport of MTX. Consistent with the latter view, we previously reported a lower risk of treatment failure in children with ALL in whom plasma MTX concentrations were above 16 AtM following HDMTX therapy, indicating the potential importance of achieving higher extracellular MTX concentrations (1, 8) .
Advocates of LDMTX also argue that high concentrations of MTX may impair formation of MTX-polyglutamates (MTX-PG) through feedback inhibition, as has been demonstrated in vitro (9-1 1). Metabolism of MTX to its polyglutamated metabolites, especially long-chain polyglutamates (i.e., MTX-glu4-6), is considered important for maximum pharmacologic effects (12) . These active MTX-PG metabolites are formed by folylpolyglutamate synthetase (FPGS), the enzyme that catalyzes synthesis of polyglutamated forms of natural folates as well as antifols such as MTX. Methotrexate polyglutamates, particularly those with more than three glutamyl residues, are retained in cells longer than MTX, providing a mechanism by which MTX-PGs may produce greater cytotoxicity (13) (14) (15) (16) . Moreover, MTX-PGs inhibit not only dihydrofolate reductase (DHFR) (17, 18) , they also inhibit other folate-dependent enzymes that are not substantially inhibited by MTX, such as thymidylate synthase (19) and transformylases required for de novo purine synthesis (20) . The absence of MTX-PG formation has been established as a mechanism by which cancer cells can develop resistance to MTX (21) (22) (23) (24) . In this regard, Whitehead et al. (25) On day 4, all patients began conventional remission induction therapy with six drugs (i.e., prednisone, vincristine, daunomycin, asparaginase, etoposide, and cytosine arabinoside) given over 29 d in the dosages and schedules previously described in detail (31) . The use of etoposide (300 mg/m2 per dose) instead of teniposide, and the omission of daunomycin on day 15, were the only major changes from the previously reported remission induction therapy (31) .
Blood sample collection and analysis. Blood was obtained before and at 1, 6, 23, 44, and 68 h after the start of HDMTX infusion. In patients receiving LDMTX, blood was obtained before doses 1 and 2; before and 1, 1.5, 2, and 6 h after dose 4; and then at 14 and 38 h after dose 6. Plasma samples were analyzed for MTX by a fluorescence polarization immunoassay (Abbott TDx; Abbott Laboratories, North Chicago, IL). Pharmacokinetic parameters were estimated assuming a first-order two compartment model, using a Bayesian estimation algorithm, as implemented in ADAPT II software (32) . The prior distribution for model parameters was based on previous data in children who received HDMTX or LDMTX (1, 33) . To assess the relationship between MTX systemic exposure and leukemic blast MTX-polyglutamate concentrations, the MTX steady-state plasma concentration at hour 23 of the 24-h infusion was used as the measure of systemic exposure in patients receiving HDMTX, while the model estimated steady-state peak MTX concentration (after dose 4) was used in the LDMTX group.
Bone marrow sample collection and analysis. To measure MTX-PG concentrations in ALL blasts, a bone marrow aspirate was performed 44 h after the start of MTX therapy, before leucovorin rescue. Samples of 2-10 ml of bone marrow were collected in syringes containing 800 u of heparin. Leukemic blast cells were isolated by Ficoll-Hypaque gradient and washed three times in cold culture media (RPMI 1640 containing 10% fetal bovine serum and 2 mM L-glutamine). The final cell yield was determined by hemacytometer and percent viability by trypan blue exclusion. Cells (2 5 X 106) were extracted for analysis using a modification of the method of Kamen and Winick (34) .
Methotrexate and six polyglutamated metabolites (MTX-glu2 to MTX-glu7) were separated using a previously reported HPLC method (35) . The column eluent was collected in fractions determined by the elution times of each polyglutamated metabolite (MTX-glu2 to MTXglu7, obtained from Schircks Laboratories, Jona, Switzerland). Each fraction was dried to completion and assayed using a radio-ligand binding assay (The Enzyme Center, Inc., Malden, MA) (36) . Separate calibration curves were used for quantitation of MTX and each polyglutamated metabolite. patients (P = 0.0002) had total MTX-PG > 500 pmol/109 cells, an in vitro level previously associated with a favorable outcome in ALL (25) . Patients treated with HDMTX also had significantly higher concentrations of long-chain MTX-PGs (i.e., MTX-glu4-6, 986 vs 355 pmol/109 cells; P = 0.001). MTX-glu5 was the predominant MTX-PG in both HDMTX (60%) and LDMTX (65%) patients, while MTX-glu6 was the predominant MTX-PG in 15% of HDMTX patients versus 3.7% of LDMTX patients. MTX-glu7 was detectable in most patients (81%), however, it represented < 2% of the total MTX-PG in both treatment groups and levels were typically near the limit of assay quantitation.
While the median MTX-PG concentration was threefold higher in patients treated with HDMTX compared to LDMTX, there was substantial interindividual variability within both treatment groups. As depicted in Fig. 3 (circles) , a small number of patients treated with LDMTX (n = 5, 9%) had blast MTX-PG concentrations comparable to the median for the HDMTX group, and a small number of HDMTX patients (n = 6, 13%) had blast MTX-PG below the median for LDMTX patients. MTX, methotrexate (glul). MTX-glu5 was the predominant MTX-PG in 62% of patients, while MTX-glu3 or MTX-glu4 was the predominant form in 11.8% and 12.7% of patients, respectively. Circles depict total MTX-PG (i.e., MTX-glu2-6) measured in blasts from each patient, horizontal bars depict median value in each group, P value indicates statistical significance in total MTX-PG in HDMTX versus LDMTX. (Inset) HPLC separation of MTX and each polyglutamate metabolite. Characteristics related to MTX-polyglutamate concentrations in ALL blasts. The basis of interpatient variability in blast MTX-PGs was explored by analysis of patient and blast cell characteristics. When assessed by univariate analysis, higherdose, higher MTX plasma concentration, B-lineage, hyperdiploidy (> 50 chromosomes) and higher %S were each significantly associated with higher blast MTX-PG concentrations (Table II) .
Given the relatively small number of hyperdiploid T-lineage patients, multiple regression analysis was limited to B-lineage patients (n = 87). Since MTX dose and plasma concentration were correlated, they were not included simultaneously in the model; however, the final model was the same whether MTX dose (HDMTX vs LDMTX) or plasma concentration (< 5 gM vs 2 5 ,uM) was included. In either case, higher dose (or plasma concentration), hyperdiploidy, and higher %S were significantly associated with higher blast MTX-PG concentration (rd = 0.42, P < 0.0001; n = 76, 11 patients did not have %S determined).
Differences in MIX-PG concentrations in B-lineage versus T-lineage lymphoblasts. Since hyperdiploid blasts accumulated higher MTX-PG concentrations than non-hyperdiploid blasts (Table II) and hyperdiploidy is rare in T-lineage ALL, further assessment of lineage differences was confined to nonhyperdiploid ALL (n = 76; 63 B-lineage and 13 T-lineage).
As depicted in Fig. 4 , the median blast MTX-PG concentration was significantly higher in B-lineage blasts than T-lineage blasts within each dosage group (LDMTX, 474 vs. 149 pmol/ 109 cells, P = 0.001 and HDMTX, 1413 vs. 552 pmol/109 cells, P = 0.03). Long-chain MTX-glu4-6 concentrations were significantly higher in B-lineage than in T-lineage blasts following LDMTX therapy (median 351 vs 51, P < 0.001, Fig. 4) , while the lineage difference was not significant after HDMTX (median 1025 vs 437, P = 0.13). Patients with T-lineage ALL treated with HDMTX had blast MTX-PG concentrations similar to those achieved in B-lineage patients treated with LDMTX (577 vs. 488 pmol/109 cells, P = 0.78). This was also true for long-chain MTX-glu4-6 (442 vs. 323 pmol/109 cells, P = 0.67).
Leukemic ploidy and blast MIX-PG concentrations. Assessment of leukemic cell ploidy as a determinant of MTX-PG accumulation was limited to only B-lineage ALL, due to the low prevalence of hyperdiploidy (> 50 chromosomes) in Tlineage ALL and the significant difference between T-lineage and B-lineage blasts in the accumulation of MTX-PG (as described above). As shown in Fig. 4 , blasts from patients with hyperdiploid ALL (n = 21) accumulated higher concentrations of MTX-PGs than blasts from patients with nonhyperdiploid ALL (n = 63) (LDMTX: 758 vs. 474 pmo/lO9 cells, P = 0.01; HDMTX: 3371 vs. 1413 pmol109 cells, P = 0.055). Although MTX-glU5 was the predominant polyglutamate in hyperdiploid and nonhyperdiploid patients treated with either HDMTX or LDMTX, hyperdiploid blasts accumulated significantly higher concentrations of long-chain MTX-glu4-6 in both treatment groups (P < 0.04 and P < 0.01, respectively). Nonhyperdiploid ALL patients treated with HDMTX had blast MTX-PG concentrations similar to those achieved in hyperdiploid blasts treated with LDMTX (1339 vs. 832 pmol/109 cells; P = 0.09); this was also true for long-chain MTX-glu4-6 (995 vs. 736 pmol/ 109 cells; P = 0.30). There was no single chromosomal duplication that correlated with higher blast MTX-PG among hyperdiploid cases. The mean (range) fraction of cells in S-phase was significantly higher in hyperdiploid blasts 8.9% (1.5-16.3) , when compared to nonhyperdiploid blasts 4.8% (0.4-27.6); however, both ploidy and %S were significant independent variables in the multiple regression model, indicating that higher MTX-PG in hyperdiploid blasts was not entirely due to differences in %S.
Discussion
This study has established that HDMTX (1 g/m2 infused i.v. From a clinical perspective, it is noteworthy that HDMTX produced MTX-PG concentrations in T-lineage blasts comparable to B-lineage blasts treated with LDMTX, suggesting a strategy to at least partially circumvent the lineage differences in MTX-PG concentrations. As such, this may provide an explanation for the recently reported improved outcome of patients with T-lineage ALL treated with regimens incorporating HDMTX (e.g., 5 g/m2) (43) . The present study also establishes that higher doses of MTX are necessary in patients with nonhyperdiploid B-lineage ALL, if one wishes to achieve intracellular MTX-PG levels comparable to hyperdiploid B-lineage blasts in patients treated with low dose MTX. Collectively, these data provide a solid rationale for using HDMTX in the treatment of childhood ALL, and indicate that this may be especially important for patients with T-lineage or nonhyperdiploid B-lineage ALL, disease characteristics associated with a worse prognosis on conventional therapy. 
